Introduction
E s o p h a g e a l a n d g a s t r i c v a r i c e s a r e c o m m o n complications of chronic liver diseases. On the other hand, esophageal varices are one of the most common causes of acute upper gastrointestinal bleeding (1, 2) . The 6-week mortality rate of each variceal bleeding episode is 15-20%, ranging from 0% among patients with Child class A to approximately 30% among patients with Child class C (3) (4) (5) . Before the 1970s, the major treatment options of variceal bleeding included vasoconstrictors and surgical intervention. Since the mid-1970s, endoscopic injection sclerotherapy (EIS) has been gradually employed for the treatment of esophageal variceal bleeding (6) . EIS is superior to vasoconstrictors or balloon tamponade in controlling acute esophageal variceal bleeding (7, 8) . However, EIS is associated with a number of complications, such as esophageal ulcer, stenosis, and perforation (9) . Among them, the incidence of ulcer related bleeding after EIS is 4.3-12.8% (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . At present, there is no consensus on the treatment strategy for esophageal ulcer-related bleeding after EIS. In this article, we reported a case of esophageal ulcer related bleeding after EIS and discussed the management of this complication.
Case presentation
On June 17, 2018, a 36-year-old male with a 19-month history of hepatitis C virus related liver cirrhosis was admitted to the Department of Emergency of our hospital due to intermittent hematemesis for 11 hours.
Summary
Esophageal variceal bleeding is a common lethal complication of cirrhosis. Endoscopic injection sclerotherapy (EIS) is one of the major endoscopic approaches for treating esophageal variceal bleeding. However, complications may occur after EIS, which mainly include retrosternal discomfort/pain, dysphagia, re-bleeding, esophageal ulcer, esophageal strictures, and esophageal perforation, etc. In this article, we reported a 36-year-old male who developed esophageal ulcer related bleeding after EIS. Currently, there is no consensus on the treatment strategy for esophageal ulcer-related bleeding after EIS. In the present case, the following treatment strategy may be effective for ulcer related bleeding. The first step is to inhibit gastric acid secretion and reduce portal pressure by intravenous infusion of esomeprazole and somatostatin, respectively. The second is local hemostasis by oral norepinephrine and lyophilizing thrombin powder. The third is to protect digestive tract mucosa by oral Kangfuxin Ye and aluminum phosphate. . Sclerotherapy with lauromacrogol 5 mL followed by tissue adhesive 0.5 mL was successfully performed by our endoscopist (Figure 2 ). After endoscopic treatment, terlipressin and esomeprazole were discontinued. Oral propranolol 10 mg per 12 hours was given.
On June 21, 2018, the patient developed hematemesis after sneezing. The volume of fresh blood vomited was about 100ml. Laboratory tests demonstrated that WBC was 4.8 × 10 9 /L, GR% was 66.9%, RBC was 3.81 × 10 12 /L, Hb was 117 g/L, HCT was 35.8%, TBIL was 53.9 μmol/L, DBIL was 34.5 μmol/L, ALT was 25.55 U/L, AST was 37.92 U/L, AKP was 124.34 U/L, GGT was 33.1 U/L, and ALB was 29.8 g/L. Infusion of somatostatin 3,000 u per 12 hours and esomeprazole 80 mg per 10 hours was given.
On June 22, 2018, endoscopy showed two ulcer lesions (Figure 3 ). At 15:00 o'clock, the patient developed hematemesis again. The volume of fresh blood vomited was about 100 mL. Laboratory tests demonstrated that WBC was 4.8 × 10 9 /L, GR% was 76.1%, RBC was 3.65 × 10 12 /L, Hb was 114 g/L, and HCT was 34.6%. Intravenous infusion of esomeprazole 80 mg per 10 hours was continued. The dosage of somatostatin was changed to 3,000 u per 6 hours. In addition, intravenous infusion of carbazochrome sodium sulfonate 80 mg per day and oral lyophilizing thrombin powder 5,000 u per day, norepinephrine 4 mg per day, and aluminum phosphate 20 g three times a day were given.
On June 24, 2018, the patient developed hematemesis again. The volume of fresh blood vomited was about 10 mL. Oral lyophilizing thrombin powder 5,000 u per day and norepinephrine 2 mg per day were given again. On July 1, 2018, the patient did not have hematemesis or melena. Somatostatin, levofloxacin, and carbazochrome sodium sulfonate were discontinued.
On July 4, 2018, the patient did not have hematemesis and then was discharged. Laboratory tests demonstrated that WBC was 3.2 × 10 9 /L, GR% was 77%, RBC was 3.37 × 10 12 /L, Hb was 111 g/L, HCT was 32.5%, TBIL was 31.7 μmol/L, DBIL was 21.4 μmol/L, ALT was 8.20 U/L, AST was 22.94 U/L, AKP was 103 U/L, GGT was 28.89 U/L, and ALB was 31.7 g/L. We recommended the patient to take medication at home, including oral Kangfuxin Ye 10 mL per day, aluminum phosphate 20 g per day, propranolol 10 mg twice a day, and polyene phosphatidylcholine 456 mg three times a day.
On August 6, 2018, the patient underwent follow-up endoscopic surveillance. Laboratory tests demonstrated that WBC was 2. 
Discussion
Currently, the first-line treatment option of acute variceal bleeding should be endoscopic treatment combined with vasoconstrictors (20) . However, according to the current practice guideline, covered transjugular intrahepatic portosystemic shunt (TIPS) should be considered as the treatment of choice in the cases when endoscopic On June 26, 2018, the patient did not have hematemesis or melena. Laboratory tests demonstrated that WBC was 4.1 × 10 9 /L, GR% was 71%, RBC was 3.63 × 10 12 /L, Hb was 116 g/L, HCT was 35.4%, TBIL was 45.5 μmol/L, DBIL was 28.0 μmol/L, ALT was 13.95 U/L, AST was 22.92 U/L, AKP was 108 U/L, GGT was 28.57 U/L, ALB was 27.0 g/L, PT was 23.4 seconds, and INR was 2.07. Isoglycyrrhizinate was discontinued. The dosage of somatostatin was changed to 3,000 u per 12 hours. Albumin 10 g per day was given. Oral Kangfuxin Ye, which is a traditional Chinese medicine drug for treatment of the damage of digestive tract mucosa, 10 mL per day was given.
On June 27, 2018, the patient developed hematemesis again. The volume of fresh blood vomited was about 30 mL. Intravenous infusion of somatostatin was changed to treatment fails (21) . Our case underwent endoscopic treatment for variceal bleeding many times. We recommended the use of TIPS, but he and his relatives refused.
EBL should be preferred, when endoscopic treatment is considered for the management of acute variceal bleeding in cirrhotic patients (20, 21) . Among the patients with acute esophageal variceal bleeding, the rate of rebleeding in patients treated with EBL was lower than in those treated with EIS. The reason may be that EIS led to a sustained rise in hepatic venous pressure gradient, followed by an increased re-bleeding rate (22) . A metaanalysis demonstrated that EBL was superior to EIS in terms of re-bleeding, complications, and variceal eradication (23) . However, in our case, three visible thrombi were densely arranged on the surface of varices. Our endoscopist suggested that the ligation ring would pass over the thrombi and then lead to active bleeding during the procedure, if EBL was continued. Indeed, the American Society for Gastrointestinal Endoscopy (ASGE) guideline recommends that EIS may be performed in the case that EBL is technically difficult (24) . After a comprehensive consideration, EIS was finally performed.
Adverse events of EIS include fever, retrosternal discomfort/pain, dysphagia, injection-induced bleeding, esophageal ulcers, esophageal strictures, esophageal perforation, pleural effusion, acute respiratory distress syndrome, and infection (9, 25) . Our case developed esophageal ulcer related bleeding after EIS (Figure 3) . We reviewed the literature regarding the occurrence of re-bleeding secondary to esophageal ulcer after EBL or EIS (Table 1) . As for most of esophageal ulcers without bleeding after EIS, no special treatment was required (15) . The prophylactic use of acid suppression drugs after endoscopic treatment for gastroesophageal varices remains uncertain (26) . By comparison, as for active bleeding secondary to esophageal ulcers, endoscopic injection of epinephrine might be useful for hemostasis (15) . Our case had active ulcers bleeding after EIS. Our treatment strategy was as follows: the first was to inhibit gastric acid secretion and reduce portal pressure by intravenous infusion of esomeprazole and somatostatin, respectively; the second was local hemostasis by oral norepinephrine and lyophilizing thrombin powder; the third was to protect digestive tract mucosa by oral Kangfuxin Ye and aluminum phosphate ( Figure 5 ). Despite his ulcer related bleeding stopped, the duration of treatment was long.
In conclusion, esophageal ulcer is a major cause of early re-bleeding after EIS. However, at present, there is no consensus regarding treatment strategy of esophageal ulcer related bleeding after EIS. Our successful treatment strategy may be validated in a large-scale study.
